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The remarkable advancements in basic stem cell research with implications for several central nervous
system disorders have so far not been translated into clinically effective therapies. Here I discuss some of
the underlying problems and how they could be overcome.Introduction
The first attempt to treat a central nervous
system (CNS) disorder with cell trans-
plantation took place three decades
ago (Backlund et al., 1985). In this study,
autologous adrenal medulla cells were
implanted into the striatum of Parkinson’s
disease (PD) patients to provide a local
catecholamine source, but the beneficial
effects were minimal. A few years later,
human fetal mesencephalic tissue rich in
dopaminergic neuroblasts was trans-
planted to the striatum in PD patients.
These clinical trials established some
important basic principles of cell therapy
for CNS disorders: grafted neurons can
replace dead host neurons in the
diseased, 50- to 60-year-old human brain,
reinnervate denervated areas, release
transmitter, and, in some patients, give
rise to therapeutically valuable effects
(Lindvall and Kokaia, 2010). Based on
these findings, stem-cell-based therapy
for PD has been regarded as a low-
hanging fruit, with the requirement for
successful treatment being seemingly
simple, namely to generate large numbers
of standardized dopaminergic neurons for
transplantation from stem cells. However,
despite major efforts in basic and clinical
research, there is still no clinically compet-
itive cell therapy for PD or any other CNS
disorder. Clinical trials with stem cells,
often of bone marrow origin, are ongoing
in, e.g., stroke, amyotrophic lateral scle-
rosis (ALS), and spinal cord injury (http://
www.clinicaltrials.gov), but whether they
will show efficacy is unclear. From my
perspective, there are several major prob-
lems that explain why the clinical transla-
tion of stem cells for neurological disease
is so difficult, as outlined below.660 Cell Stem Cell 10, June 14, 2012 ª2012The Problem of Generating the
Right Cells and Understanding
Their Mechanisms of Action
Stem cells can act in brain diseases by
replacing those cells that have died, but
they can also restore function through
other mechanisms (Lindvall and Kokaia,
2010). In the case of cell replacement,
disease pathology determines which cells
have to be generated from the stem cells.
Different cells will be needed for different
diseases. Substantial improvement in PD
and ALS will require cells with the pro-
perties of dopaminergic and motor
neurons, respectively. The situation for
cell replacement in Alzheimer’s disease
(AD) is much more complex because
the stem cells would have to be prediffer-
entiated in vitro into many different
types of neuroblasts for subsequent
implantation into a large number of brain
areas. Similarly, in stroke there is a loss
of several different types of neuron, glial
cells, endothelial cells, and parenchyma.
These broad defects raise the question
of whether it is realistic to expect that
clinically valuable improvement in disor-
ders like AD or stroke could be achieved
through cell replacement.
Importantly, efficacious cell replace-
ment will require the generation of the
correct neuronal phenotype. For ex-
ample, in PD it is not sufficient to generate
just any type of dopaminergic neuron.
Rather, to induce substantial clinical
benefit, the human stem-cell-derived
dopaminergic neurons must exhibit the
specific properties of the neurons that
have died, i.e., the substantia nigra
neurons (Lindvall et al., 2012). A recent
study did succeed in showing efficient
conversion of human embryonic stemElsevier Inc.cells into bona fide substantia nigra dopa-
minergic neurons using a differentiation
protocol guided by developmental
principles (Kriks et al., 2011). These cells
ameliorated PD symptoms after trans-
plantation in animal models without
forming tumors.
For optimum recovery in many CNS
diseases, neuronal replacement and at
least partial reconstruction of circuitry
should probably be the long-term goal.
However, a large number of experimental
studies in animal models of these disor-
ders have demonstrated that stem cell
delivery gives rise to functional improve-
ments that cannot be explained by
neuronal replacement. These beneficial
effects may also be relevant in clinical
settings. For example, systemic or intra-
cerebral delivery of neural and other
stem cells in stroke models has been
reported to lead to improvements by
trophic actions, modulation of inflamma-
tion, promotion of angiogenesis, remyeli-
nation and axonal plasticity, and neuro-
protection (Lindvall and Kokaia, 2010).
The functional effects can be enhanced
if the stem cells have been genetically
modified to secrete various factors such
as trophic molecules. For clinical compet-
itiveness, it is necessary, though, that the
efficacy and safety of the stem-cell-based
approach is superior to that of available
treatments (e.g., drugs) acting on the
same targets. Clinical trials are ongoing
in stroke and ALS with delivery of stem
cells, which are intended to act not by
neuronal replacement but instead through
one or more of the other presumed mech-
anisms. However, it is conceivable that
effective therapies will not be developed
until the mechanisms of action of the
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and can therefore be optimized.
The Problem of Using the Right
Animal Model and Behavioral Tests
Available animal models of CNS diseases
do not mimic all aspects of the pathology
of the human condition, which may
explain lack of efficacy of cell therapy
when it is translated to the clinical setting
(Lindvall et al., 2012). For example, animal
models of PD are mostly based on lesions
of the nigrostriatal dopaminergic path-
way, induced by toxins, and studies of
sensorimotor functions. These models
do not imitate the clinical disorder, which
has many nonmotor and motor features
with nondopaminergic pathology outside
the substantia nigra. Attempts to develop
transgenic models of PD have been
pursued in recent years, but these repre-
sent only partial models of the core
pathologies. For efficient clinical transla-
tion, better animal models that reflect
the complex pathology and pathogenesis
of CNS disorders accurately have to be
developed through collaboration between
basic scientists and clinicians. Many
current models use otherwise healthy,
young animals, which again is distinct
from the clinical situation in many neuro-
degenerative diseases, where patients
are often older, with concurrent diseases
and chronic medication. For example,
stroke patients frequently also suffer
from hypertension and diabetes.
The animal models may not be able to
fully predict the adverse events, toxicity
of the cell product, immune and other
biological responses, and risk for tumor
formation that would occur after implan-
tation of cells into patients. A lesson can
be learned from the clinical trials with fetal
dopaminergic cell therapy in PD. When
troublesome graft-induced involuntary
movements (so-called dyskinesias) were
observed in patients (Freed et al., 2001),
this side effect came as a surprise
because none of the preclinical studies
in rodent and primate models of PD had
observed any adverse responses of this
type. The risk of tumor formation from
cells derived from pluripotent cells also
makes clinical translation difficult. For
example, life expectancy is virtually
normal in PD patients, and therefore
even a minor risk of tumor formation
associated with stem cell therapy would
be unacceptable. It is difficult to assessthe clinical tumor risk with human embry-
onic stem cell derivates using preclinical
xenograft studies (Erdo¨ et al., 2003).
Thus, for clinical translation, there will
need to be rigorous mechanisms for
determining the tumorigenicity of stem
cells and their derivatives.
A prerequisite for application in patients
must be a demonstration in an animal
model that a given cell-based approach
induces substantial improvement of
clinically relevant functional deficits
(Lindvall et al., 2012). For example,
in rodent models of PD, behavioral
improvement after stem cell therapy is
often reported as a reversal of rotational
asymmetry in animals with unilateral
lesions of the nigrostriatal dopaminergic
system. While this test gives a good
measure of the dopamine-releasing
capacity of the grafts, the deficit does
not reflect any symptom seen in PD
patients. Other behavioral tests are
available but have only been used in
few studies. Basic scientists and
clinicians together have to develop
functional and behavioral tests that
assess deficits in animals resembling
the impairments in patients with CNS
disorders.
The Problem of Distribution
and Progression of Pathology
Even if stem cells improve function in
a specific area by neuronal replacement
or other mechanisms, effective therapy
is hindered if there is concurrent degener-
ation in other brain regions or if such
changes develop after transplantation.
For example, dopaminergic denervation
in areas not reached by the intraputaminal
grafts, such as the ventral striatum, in
PD patients with fetal dopaminergic
grafts counteracts the symptomatic relief
following transplantation (Piccini et al.,
2005). Similarly, even if replacement
of motor neurons in the spinal cord of
ALS patients did work, central motor
neurons such as corticospinal neurons,
which also degenerate in ALS, would
most likely have to be replaced for effec-
tive, life-saving restoration of function.
For successful, long-term clinical efficacy
of stem cells in chronic neurodegenera-
tive disorders, patient selection will be
crucial, and neuronal replacement prob-
ably has to be combined with a neuro-
protective therapy to hinder disease
progression.Cell Stem CellIn chronic neurodegenerative disor-
ders, host pathology may also affect the
cells derived from the transplanted stem
cells, as has been observed in fetal grafts
after implantation in PD and Huntington’s
disease patients (Kordower et al., 2008;
Cicchetti et al., 2009). This consideration
may be particularly relevant when
patient-specific cells for transplantation
are produced by therapeutic cloning,
from induced pluripotent stem cells, or
by direct conversion of somatic cells.
Such cells could exhibit increased
susceptibility to the neurodegenerative
disease process. In the case of PD, this
problem may not be a serious one,
because with fetal grafts the propagation
of disease pathology is slow, the majority
of grafted neurons are unaffected after
a decade, and the patients can experi-
ence long-term improvement.
The Problem of Translating Basic
Research Findings to Patients
A major problem hindering effective
translation is, in my view, insufficient
communication between basic scientists
and clinicians. My own experience as
a clinical neurologist is that the clinic and
the basic research laboratory are often
completely different worlds. For basic
stem cell research to have more impact
on the clinical challenges, clinicians have
to be involved from an early stage and
not just immediately before application
in patients. Basic scientists should be
educated in the clinical features of CNS
disease and the problems related to diag-
nosis and therapy. The critical scientific
steps from basic research to patient
application should be defined through
cooperation between basic scientists
and clinicians. This partnership must
function throughout all stages of clinical
translation if basic research findings are
to be efficiently converted to novel treat-
ments for CNS disorders. The new
imaging techniques for monitoring brain
and spinal cord in vivo in animals and
humans will create golden opportunities
for fruitful interaction between basic
scientists and clinicians. It is important
to emphasize that successful clinical
application of stem cells will depend not
just on the generation of the right type of
cell but also on several other factors,
such as appropriate site of delivery of
the cells and selecting the suitable
patient.10, June 14, 2012 ª2012 Elsevier Inc. 661
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Therapeutic Approaches
There is considerable variation in terms of
the availability of existing therapeutic
options for different CNS disorders, and
these differences will influence how
quickly stem cells can be translated to
the clinic. For example, to be clinically
competitive in PD, grafts must give rise
to major recovery (at least 70%) of motor
function. Motor symptoms in PD patients
can already be treated quite well with
L-dopa, DA agonists, enzyme inhibitors,
and deep brain stimulation. Thus, the
efficacy of stem cell grafts in relieving
disease symptoms would need to be
high. If transplantation of stem-cell-
derived dopaminergic neurons in a PD
patient gave only a 30% reduction in
motor symptoms, it would be regarded
as scientifically exciting but clinically
useless. The efficacy of currently available
human stem-cell-derived dopaminergic
neurons and predictions for the clinical
setting are unclear, presenting a problem
for clinical translation. As a first step
toward patient application, a cell-potency
assay should be used to compare the
efficacy of the stem-cell-derived neurons
versus equivalent fetal dopaminergic
neurons (which can be regarded as the
gold standard) in appropriate animal
models of PD.
Many brain diseases, however, lack
effective current treatments. Several
such diseases are progressive and ulti-
mately fatal, such as ALS or Huntington’s
disease. In these conditions, even a minor
improvement induced by stem cells
would be clinically useful. If efficacious
therapy is lacking, the severity of adisease
such as ALS or Huntington’s disease
might justify the risks of a stem-cell-based
experimental intervention in patients. It
should be emphasized, however, that
even when there is no effective alternative
therapy, no application in patients can
be justified if it does not have proven
efficacy in the laboratory and scientific
understanding of the mechanism of
action. For these CNS disorders, careful,
laborious, and time-consuming preclin-662 Cell Stem Cell 10, June 14, 2012 ª2012ical studies are also required. Clinical
trials showing safety alone, without any
scientific grounding for their use, are
unethical.
The Problem of Costs
Stem-cell-based treatments for CNS
disorders should not only relieve human
suffering but also be cost-effective
compared to other therapies. To promote
clinical translation, scientists should
perform health economics studies at an
early stage to estimate the potential value
of further research in stem cell therapy
for various disorders in order to ensure
that society makes the best use of
research investments. Using health
economics modeling and a range of
assumptions, it is possible to determine
which patients should be targeted with
stem cell therapy. Moreover, such
modeling will give a price at which the
intervention would be cost neutral, i.e.,
the stem cell therapy would bear its own
cost from a societal perspective. This
estimated price for stem cell therapy will
be important for companies manu-
facturing the stem-cell-based product to
be delivered to the patient. Translation of
discoveries in basic stem cell research
into safe and effective clinical products
for CNS disorders will be very expensive.
The European Court of Justice recently
decided that no patents can be granted
for inventions based on human embryonic
stem cells, even if the cell lines were
established in the laboratory many years
ago and the invention itself does not
involve obtaining new embryonic stem
cells. This decision may well cause
companies in Europe to be reluctant
to invest in translational stem cell
research because they would be unable
to protect their procedures via the patent
system. The end result will unfortunately
be further delay in the development of
clinically effective stem cell therapies for
CNS disorders.
Conclusions
Many CNS disorders in humans currently
lack effective treatments, but there isElsevier Inc.now reason to be optimistic. Experimental
studies have clearly indicated that stem
cells have the potential to give rise to
radical new therapies for these diseases.
However, there is no fast track for stem
cells to the clinic. Strong investigative
basic research remains fundamental for
clinical advancement of stem-cell-based
approaches. For efficient clinical transla-
tion, a road map to the clinic, taking into
account the critical scientific, clinical,
regulatory, and ethical issues, should be
defined and continuously revised by basic
scientists and clinicians together. The
commitment must be long term, and the
aims must be realistic. The biological
problems that will be encountered along
the way are complex and should not be
underestimated.REFERENCES
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